The report covers aspects such as pharmaceutical market segment (by Prescription & OTC Drugs, by Patented & Generic Drugs)... For more information on the research report, refer to below link: https://www.kenresearch.com/healthcare/pharmaceuticals/singapore-pharmaceutical-market/149668-91.html

1. Singapore Pharmaceutical Market is driven by Public Private
Partnerships in R&D and Expansion of Multinational
Companies in Local Market: Ken Research

2. World Class manufacturing facilities, skilled workforce, expansion of product portfolio by major
pharmaceutical companies, government grants and tax incentives were the key factors driving growth in
Singapore pharmaceutical Market.
Singapore Pharmaceutical Market can be characterized by the presence of best-in-class infrastructure,
integrated and advanced hubs for pharmaceutical manufacturing and research and access to regional
markets and skilled workforce. The government has invested in forming competitive clusters to attract
research, clinical trials, and manufacturing companies in the pharmaceutical sector. This includes
developing infrastructure such as Biopolis, and the Tuas Biomedical Park, tax breaks and business
incentives and funding of public-sector research institutes.

3. Research and Development forms an essential part of the pharmaceutical industry. Various multinational
companies have been involved in private-public partnerships in Singapore, particularly with R&D and
clinical trials. The Contract Research Organization (CRO) market in Asia grew at a rate of 20% in 2017,
with Singapore’s A*STAR leading some of the clinical growth. Few established R&D partnerships in
Singapore include Roche’s (Basel, Switzerland) Singapore Hub for Translational Medicine,
GlaxoSmithKline’s (Brentford, UK) Academic Centre of Excellence, and Bayer Healthcare’s
(Leverkusen, Germany) partnership with the Singapore National Eye Center (SNEC).
Singapore currently hosts more than 50 international biomedical science companies, including
GlaxoSmithKline, Takeda, Pfizer, Novartis and Roche. As a result of Singapore’s robust infrastructure,
intellectual property (IP) protection, access to regional markets and skilled workforce, many leading
biomedical companies have selected Singapore as their global manufacturing base for a wide range of
products including Active Pharmaceutical Ingredients, drug products and biologics drug substances.

4. Singapore pharmaceutical market will continue to incline at a positive growth rate owing to increased
investment in biopharmaceutical manufacturing, and growing Contract Research Organization market
The report titled “Singapore Pharmaceutical Market Outlook to 2022 - by Prescription & OTC
Drugs and by Patented & Generic Drugs” by Ken Research suggested a growth at a CAGR of 6.8% in
revenue in Singapore Pharmaceutical Market by 2022. Singapore Pharmaceutical market can be
characterized by the presence of best-in-class infrastructure, integrated and advanced hubs for
pharmaceutical manufacturing and research & access to regional markets and skilled workforce. Many
leading biomedical companies such as AbbVie, Pfizer, Ferring Pharmaceuticals and others have selected
Singapore as their global manufacturing base
For more information on the research report, refer to below link:
https://www.kenresearch.com/healthcare/pharmaceuticals/singapore-pharmaceutical-
market/149668-91.html

5. Related Reports by Ken Research
https://www.kenresearch.com/healthcare/pharmaceuticals/vietnam-pharmaceutical-
market/143605-91.html
Currently all patented drugs are imported for local consumption. Widely imported patented drugs
include high-value specialty drugs for oncology and diabetes management.
https://www.kenresearch.com/healthcare/pharmaceuticals/indonesia-pharmaceutical-
market/143542-91.html
Majority pharmaceutical companies are located in West Java and Jakarta due to favorable tax
incentives, well developed infrastructure and greater access to medicinal herbs.
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204